Hereditary hemochromatosis

Minerva Medica

Volumn 99, Issue 6, 2008, Pages 605-617

  Fix, O K ^a   Kowdley, K V ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VIRGINIA MASON MEDICAL CENTER   (United States)

^c BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

Genetic diseases; Hemochromatosis ; Inborn ; Mutation

Indexed keywords

IRON;

HEMOCHROMATOSIS; HUMAN; IRON DEPLETION; IRON METABOLISM; IRON OVERLOAD; LIVER CANCER; LIVER TRANSPLANTATION; PHLEBOTOMY; REVIEW; SCREENING;

HEMOCHROMATOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IRON; LIVER NEOPLASMS; MEMBRANE PROTEINS; MUTATION; PENETRANCE;

EID: 59649107237     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Adams PC, Barton JC. Haemochromatosis. Lancet 2007;370:1855-60.
2. Phatak PD, Bonkovsky HL, Kowdley KV. Hereditary hemochromatosis: time for targeted screening. Ann Intern Med 2008;149:270-2.
3. Pietrangelo A. Hereditary hemochromatosis - a new look at an old disease. N Engl J Med 2004;350:2383-97.
4. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13:399-408.
5. Wheeler CJ, Kowdley KV. Hereditary hemochromatosis: a review of the genetics, mechanism, diagnosis, and treatment of iron overload. Compr Ther 2006;32:10-6.
6. Tavill AS. Diagnosis and management of hemochromatosis. Hepatology 2001;33:1321-8.
7. Ryan E, O'Keane C, Crowe J. Hemochromatosis in Ireland and HFE. Blood Cells Mol Dis 1998;24:428-32.
8. Merryweather-Clarke AT, Pointon JJ, Jouanolle AM, Rochette J, Robson KJ. Geography of HFE C282Y and H63D mutations. Genet Test 2000;4:183-98.
9. Steinberg KK, Cogswell ME, Chang JC, Caudill SP, McQuillan GM, Bowman BA et al. Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. JAMA 2001;285:22l6-22.
10. Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005;352:1769-78.
11. Distante S, Robson KJ, Graham-Campbell J, Arnaiz-Villena A, Brissot P, Worwood M. The origin and spread of the HFE-C282Y haemochromatosis mutation. Hum Genet 2004;115:269-79.
12. Naugler C. Hemochromatosis: a Neolithic adaptation to cereal grain diets. Med Hypotheses 2008;70:691-2.
13. Nelson JE, Kowdley KV. Non-HFE hemochromatosis: genetics, pathogenesis, and clinical management. Curr Gastroenterol Rep 2005;7:71-80.
14. Pietrangelo A. Non-HFE hemochromatosis. Semin Liver Dis 2005;25:450-60.
15. Victor A. McKusick. Hemochromatosis. In: Online Mendelian Inheritance of Man, OMIM. Johns Hopkins University, Baltimore, MD. MIM number: 235200. May 27, 2008 [accessed Sept 14, 2008]. Available at: http://www.ncbi.nlm.nih.gov/omim.
16. Brissot P, de Bels F. Current approaches to the management of hemochromatosis. Hematology Am Soc Hematol Educ Program 2006:36-41.
17. Papanikolaou G, Samuels ME, Ludwig EH, MacDonald ML, Franchini PL, Dube MP et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2004;36:77-82.
18. Roetto A, Papanikolaou G, Politou M, Alberti F, Girelli D, Christakis J et al. Mutant antimicrobial peptide hep-cidin is associated with severe juvenile hemochromatosis. Nat Genet 2003;33:21-2.
19. Camaschella C, Roetto A, Cali A, De Gobbi M, Garozzo G, Carella M et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 2000;25:14-5.
20. Roetto A, Totaro A, Piperno A, Piga A, Longo F, Garozzo G et al. New mutations inactivating transferrin receptor 2 in hemochromatosis type 3. Blood 2001;97:2555-60.
21. Montosi G, Donovan A, Totaro A, Garuti C, Pignatti E, Cassanelli S et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3.) gene. J Clin Invest 2001;108:619-23.
22. Drakesmith LI, Schimanski LM, Ormerod E, Merryweather-Clarke AT, Viprakasit V, Edwards JP et al. Resistance to hepcidin is conferred by hemochro-matosis-associated mutations of ferroportin. Blood 2005;106:1092-7.
23. Olynyk JK, Trinder D, Ramm GA, Britton RS. Bacon BR. Hereditary hemochromatosis in the post-HFE era. Hepatology 2008;48:991-1001.
24. Andrews NC. Disorders of iron metabolism. N Engl J Med 1999:341:1986-95.
25. Bridle KR, Frazer DM, Wilkins SJ, Dixon JL, Purdie DM, Crawford DH et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet 2003;361:669-73.
26. Gehrke SG, Kulaksiz H, Herrmann T, Riedel HD, Bents K, Veltkamp C et al. Expression of hepcidin in hereditary hemochromatosis: evidence for a regulation in response to the serum transferrin saturation and to non-transferrin-bound iron. Blood 2003;102:371-6.
27. Adams P, Brissot P, Powell LW. EASL International Consensus Conference on Haemochromatosis.] Hepatol 2000;33:485-504.
28. Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB. Nicoll Aj et al. Iron- overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008:358:221-30.
29. Andersen RV. Tybjaerg-Hansen A, Appleyard M, Birgens H. Nordestgaard BG. Hemochromatosis mutations in the general population: iron overload progression rate. Blood 2004:103:2914-9.
30. Asberg A. Liveem K, Kannelonning K, Irgens WO. Penetrance of the C28Y/C282Y genotype of the HFE gene. Scand J Gastroenterol 2007;42:1073-7.
31. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999;341:718-24.
32. Olynyk JK, Hagan SE, Cullen DJ, Beilby J, Whittall DE. Evolution of untreated hereditary hemochromatosis in the Busselton population: a 17-year study. Mayo Clin Proc 2004;79:309-13.
33. Gurrin LC, Osborne NJ, Constantine CC, McLaren CE, English DR, Gertig DM et al. The Natural History of Serum Iron Indices for HFE C282Y Homozygosity Associated With Hereditary Hemochromatosis. Gastroenterology 2008 [Epub ahead of print).
34. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107-19.
35. Adams PC, Deugnier Y, Moirand R, Brissot P. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology 1997;25:162-6.
36. Trousseau A. Glycosurie: diabetic sucre. Clin Med Hotel Dieu Paris 1865;2:663-98.
37. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G→ A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002;359:211-8.
38. Adams PC, Agnew S. Alcoholism in hereditary hemochromatosis revisited: prevalence and clinical consequences among homozygous siblings. Hepatology 1996;23:724-7.
39. Piperno A, Fargion S, D'Alba R, Roffi L, Fracanzani AL, Vecchi L et al. Liver damage in Italian patients with hereditary hemochromatosis is highly influenced by hepatitis B and C virus infection. J Hepatol 1992;l6:364-8.
40. Walsh A, Dixon JL, Ramm GA, Hewett DG, Lincoln DJ, Anderson GJ et al. The clinical relevance of compound heterozygosity for the C282Y and H63D substitutions in hemochromatosis. Clin Gastroenterol Hepatol 2006;4:1403-10.
41. Cheng R, Barton JC, Morrison ED, Phatak PD. Krawitt FL, Gordon SC et al. Differences in hepatic phenotype between hemochromatosis patients with HFE C282Y homozygosity and other HFE genotypes. J Clin Gastroenterol 2008 [in press].
42. Niederau C, Fischer R, Sonnenberg A. Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985:313:1256-62.
43. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.
44. Elmberg M, Hultcrantz R, Ekbom A, Brandt L, Olsson S, Olsson R et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 2003;125:1733-41.
45. Fracanzani AL, Conte D, Fraquelli M, Taioli E, Mattioli M, Losco A et al. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatologv 2001;33:647-51.
46. Adams PC, Passmore L, Chakrabarti S, Reboussin DM, Acton RT, Barton JC et al. Liver diseases in the hemochromatosis and iron overload screening study. Clin Gastroenterol Hepatol 2006:4:918-23.
47. Powell LW, Dixon JL, Ramm GA, Purdie DM, Lincoln DJ, Anderson GJ et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med 2006;166:294-301.
48. Bulaj ZJ, Ajioka RS, Phillips JD, LaSalle BA, Jorde LB, Griffen LM et al. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med 2000;343:1529-35.
49. Barton JC, McDonnell SM, Adams PC, Brissot P, Powell LW, Edwards CQ et al. Management of hemochromatosis. Hemochromatosis Management Working Group. Ann Intern Med 1998;129:932-9.
50. Aguilar-Martinez P, Schved JF, Brissot P. The evaluation of hyperferritinemia: an updated strategy based on advances in detecting genetic abnormalities. Am J Gastroenterol 2005;100:1185-94.
51. Adams PC, Reboussin DM, Press RD, Barton JC, Acton RT, Moses GC et al. Biological variability of transferrin saturation and unsaturated iron-binding capacity. Am J Med 2007; 120:999 e1-7.
52. Alexander J, Kowdley KV, Hereditary hemochromatosis: genetics, pathogenesis, and clinical management. Ann Hepatol 2005;4:240-7.
53. St Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005;105:855-61.
54. Guyader D, Jacquelinet C, Moirand R, Turlin B, Mendler MH, Chaperon J et al. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology 1998;115:929-36.
55. Kowdley KV, Trainer TD, Saltzman JR, Pedrosa M, Krawitt EL, Knox TA et al. Utility of hepatic iron index in American patients with hereditary hemochromatosis: a multicenter study. Gastroenterology 1997;113:1270-7.
56. Morrison ED, Brandhagen DJ, Phatak PD, Barton JC, Krawitt EL, El-Serag HB et al. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann Intern Med 2003;138:627-33.
57. Witte DL, Crosby WH, Edwards CQ, Fairbanks VF. Mitros FA. Practice guideline development task force of the College of American Pathologists. Hereditary hemochromatosis. Clin Chim Acta 1996;245:139-200.
58. Barton JC. Chelation therapy for iron overload. Curr Gastroenterol Rep 2007;9:74-82.
59. Falize L, Guillygomarc'h A, Perrin M, Laine F, Guyader D, Brissot P et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 2006;44:472-7.
60. Kowdley KV, Brandhagen DJ, Gish RG, Bass NM, Weinstein J, Schilsky ML et al. Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry. Gastroenterology 2005;129:494-503.
61. Kowdley KV, Hassanein T, Kaur S, Farrell FJ, Van Thiel DH, Keeffe EB et al. Primary liver cancer and survival in patients undergoing liver transplantation for hemochromatosis. Liver Transpl Surg 1995;1:237-41.
62. Yu L, Ioannou GN. Survival of liver transplant recipients with hemochromatosis in the United States. Gastroenterology 2007;133:489-95.
63. Andermann A, Blancquaert I, Beauchamp S, Dery V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ 2008;86:317-9.
64. Wilson J, Jungner G. Principles and practice of screening for disease. WHO, 1968 [accessed September 15, 2008]. Available at: http://www.who.int/ bulletin/volumes/86/4/07-050112BP.pdf.
65. Guttmacher AE, Collins FS. Welcome to the genomic era. N Engl J Med 2003;349:996-8.
66. Khoury MJ, McCabe LL, McCabe ER. Population screening in the age of genomic medicine. N Engl J Med 2003;348:50-8.
67. Adams PC, Valberg LS. Screening blood donors for hereditary hemochromatosis: decision analysis model comparing genotyping to phenotyping. Am J Gastroenterol 1999;94:1593-600.